Si-yuan Li

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Serum interleukin-6 (Il-6) monitoring in idiopathic multicentric Castleman disease: important value in patients receiving non-anti-Il-6 therapy.

Serum interleukin-6 (Il-6) monitoring in idiopathic multicentric Castleman disease: important value in patients receiving non-anti-Il-6 therapy.

Journal: Biomarker research

Published: February 14, 2026

Idiopathic Multicentric Castleman Disease-TAFRO: A Potentially Curable Disease?

Idiopathic Multicentric Castleman Disease-TAFRO: A Potentially Curable Disease?

Journal: American journal of hematology

Published: September 16, 2025

TAFRO Syndrome Without Pathology Supporting Castleman Disease: To Be Treated as Idiopathic Multicentric Castleman Disease-TAFRO or a Distinct Disease Entity?

TAFRO Syndrome Without Pathology Supporting Castleman Disease: To Be Treated as Idiopathic Multicentric Castleman Disease-TAFRO or a Distinct Disease Entity?

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: February 12, 2025

LRG1, a novel serum biomarker for iMCD disease activity.

LRG1, a novel serum biomarker for iMCD disease activity.

Journal: Biomarker research

Published: December 13, 2024

Unicentric Castleman disease complicated with bronchiolitis obliterans: A single-centre retrospective study from China.

Unicentric Castleman disease complicated with bronchiolitis obliterans: A single-centre retrospective study from China.

Journal: British journal of haematology

Published: November 02, 2024

Clinical Characteristics and Prognosis of Pediatric Idiopathic Multicentric Castleman Disease.

Clinical Characteristics and Prognosis of Pediatric Idiopathic Multicentric Castleman Disease.

Journal: American journal of hematology

Published: October 29, 2024

Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single-centre, retrospective study.

Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single-centre, retrospective study.

Journal: British journal of haematology

Published: August 14, 2024

Whole-exome sequencing assists in the diagnosis of hyperimmunoglobulin E syndrome: Insights into dual genetic abnormalities.

Whole-exome sequencing assists in the diagnosis of hyperimmunoglobulin E syndrome: Insights into dual genetic abnormalities.

Journal: Heliyon

Published: June 10, 2024

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.

Journal: Annals of hematology

Published: June 07, 2024

Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.

Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.

Journal: British journal of haematology

Published: December 24, 2023

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.

Journal: International journal of hematology

Published: October 12, 2023

Showing 1-11 of 11

Last Updated: 09/26/2026